World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
58075
World Ranking
17332
National Ranking
8685

Edward B. Garon publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Edward B. Garon sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 688 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Edward B. Garon D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Edward B. Garon sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Edward B. Garon is affiliated with the University of California, Los Angeles in the United States. Their research primarily focuses on the field of Medicine, with specific emphasis on Oncology and Pulmonary and Respiratory Medicine. Other subfields of study include Cancer Research, Molecular Biology, and Immunology.

The scientist has contributed to topics such as:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Immunotherapy and Immune Responses

Their recent published papers include:

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer, 2020, Journal of Clinical Oncology
  • Capmatinib in MET Exon 14-Mutated or MET -Amplified Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer, 2020, JAMA Oncology
  • Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study, 2023, Journal of Clinical Oncology
  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189, 2021, Annals of Oncology

Frequent co-authors include:

  • Aaron Lisberg
  • Byoung Chul Cho
  • Melissa L. Johnson
  • Enriqueta Felip
  • Rebecca S. Heist

Key publication venues for their work are:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts

Best Publications

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

    Roy S. Herbst;Paul Baas;Dong Wan Kim;Enriqueta Felip

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

    Diego Chowell;Luc G. T. Morris;Claud M. Grigg;Jeffrey K. Weber

  • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Edward B. Garon;Tudor Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash

  • Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

    Narek Shaverdian;Aaron E Lisberg;Krikor Bornazyan;Darlene Veruttipong

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee

  • Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

    Charles M. Rudin;Christine L. Hann;Edward B. Garon;Moacyr Ribeiro de Oliveira

  • Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

    Paul C. Tumeh;Matthew D. Hellmann;Omid Hamid;Katy K. Tsai

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

    Naiyer A Rizvi;Byoung Chul Cho;Niels Reinmuth;Ki Hyeong Lee

  • A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

    A. Lisberg;A. Cummings;J.W. Goldman;K. Bornazyan

  • PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

    Jyoti D. Patel;Mark A. Socinski;Edward B. Garon;Craig H. Reynolds

  • Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

    M. G. Kris;B. E. Johnson;D. J. Kwiatkowski;A. J. Iafrate

  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

    D. Rodríguez-Abreu;S.F. Powell;M.J. Hochmair;S. Gadgeel

  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

    K. Hastings;H.A. Yu;H.A. Yu;W. Wei;F. Sanchez-Vega

Frequent Co-Authors

Martin Reck
Martin Reck LungenClinic Grosshansdorf
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Steven M. Dubinett
Steven M. Dubinett University of California, Los Angeles
Roy S. Herbst
Roy S. Herbst Yale University
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
David Elashoff
David Elashoff University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean following the traditional path to an MD. There are flexible online degree options that offer specialized career opportunities and advanced credentials for healthcare professionals. For instance, registered nurses can take the next step with rn to np programs online, streamlining their journey to become nurse practitioners without putting their careers on hold.

Those interested in wellness and patient nutrition can consider earning a bachelor's in nutrition online. This credential opens doors to roles in public health, clinical settings, and community outreach.

Aspiring healthcare leaders might look to cahme-accredited online mha programs, giving graduates an edge in hospital or health system management. Meanwhile, practicing RNs seeking to advance without additional on-site requirements will find value in online rn to bsn programs no clinicals, combining flexibility and professional growth.

Each pathway supports a vital role in the evolving healthcare system, empowering students to pursue meaningful careers online.

Best Scientists Citing Edward B. Garon

Trending Scientists

Recently Published Articles